Vertex, Bristol to conduct midstage trials of hep C combo therapy

04/8/2013 | Genetic Engineering & Biotechnology News

Vertex Pharmaceuticals and Bristol-Myers Squibb signed a non-exclusive deal to initiate two midstage trials of a once-a-day combination therapy for hepatitis C. The trials will test the safety, tolerability, pharmacokinetics and viral cure rates of Vertex's VX-135, a nucleotide analogue hepatitis C virus polymerase inhibitor, in combination with Bristol's daclatasvir, an experimental NS5A replication complex inhibitor.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD